The FDA Panel Weighs In on Trendy Peptide Therapies
L'essentiel
- An FDA panel is set to review seven peptides, popular in wellness circles for injury recovery and more, but lacking large-scale trials and FDA approval.
- Concerns linger about safety and potential conflicts of interest among panel members.
Résumé généré par IA
An FDA panel is set to review seven peptides, popular in wellness circles for injury recovery and more, but lacking large-scale trials and FDA approval. Concerns linger about safety and potential conflicts of interest among panel members.






